Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $581000.0.

  • BioXcel Therapeutics' Share-based Compensation fell 6884.72% to $581000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 7872.21%. This contributed to the annual value of $6.2 million for FY2024, which is 6692.81% down from last year.
  • BioXcel Therapeutics' Share-based Compensation amounted to $581000.0 in Q3 2025, which was down 6884.72% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Share-based Compensation peaked at $6.1 million during Q2 2023, and registered a low of -$199000.0 during Q4 2024.
  • Its 4-year average for Share-based Compensation is $3.0 million, with a median of $3.6 million in 2023.
  • Per our database at Business Quant, BioXcel Therapeutics' Share-based Compensation tumbled by 10552.93% in 2024 and then skyrocketed by 4720.91% in 2025.
  • BioXcel Therapeutics' Share-based Compensation (Quarter) stood at $4.5 million in 2022, then fell by 20.85% to $3.6 million in 2023, then plummeted by 105.53% to -$199000.0 in 2024, then soared by 391.96% to $581000.0 in 2025.
  • Its Share-based Compensation was $581000.0 in Q3 2025, compared to $1.6 million in Q2 2025 and $180000.0 in Q1 2025.